These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: β-catenin deacetylation is essential for WNT-induced proliferation of breast cancer cells.
    Author: Wang SH, Li N, Wei Y, Li QR, Yu ZP.
    Journal: Mol Med Rep; 2014 Mar; 9(3):973-8. PubMed ID: 24401947.
    Abstract:
    Deregulation of the WNT signaling pathway is associated with the development and progression of breast cancer. β-catenin mutations have been found to constitutively activate β-catenin-T-cell factor (TCF) signaling in other types of cancer. β-catenin acetylation regulates β-catenin-TCF4 interaction in WNT signaling, but it remains unknown whether the acetylation of β-catenin is involved in WNT-induced proliferation of breast cancer cells. In this study, a lower level of acetylated β-catenin (K345) was observed in breast cancer tissues. WNT3A stimulated the downregulation of β-catenin acetylation and promoted the proliferation of MCF7 cells. The K345Q mutation in β-catenin inhibited WNT-induced cell growth and axin2/TCF7 upregulation in breast cancer cells. By contrast, K345R mutants could mimic deacetylated β-catenin to generate the WNT-elicited phenotype. Additionally, the acetylation of β-catenin may prime β-catenin for phosphorylation. Further investigation revealed that the deacetylase HDAC6 was responsible for WNT-induced deacetylation of β-catenin in breast cancer cells. In conclusion, the epigenetic modification of β-catenin may be essential for WNT signaling in breast cancer progression, and blocking the occurrence of β-catenin acetylation may provide a novel therapeutic approach for breast cancer.
    [Abstract] [Full Text] [Related] [New Search]